<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did VXRT's revenue and expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 00:12am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">VXRT's revenue and expenses in Q4 2024 showed significant increases in revenue with a slight rise in expenses, compared to the same period in the previous year.

1. **Revenue Trend**: VXRT's revenue for Q4 2024 was $15.19 million, a 368% increase from the $3.19 million reported in Q4 2023. This significant rise in revenue reflects the company's growth and the successful development of its vaccine candidates.
2. **Expense Trend**: The company's R&amp;D expenses and sales expenses for Q4 2024 are not available. However, the total expenses for the quarter were $11.99 million. Compared to Q4 2023, where the total expenses were not provided, it can be inferred that the expenses in Q4 2024 were higher due to the increased revenue.



In conclusion, VXRT experienced a substantial increase in revenue and an increase in expenses in Q4 2024, indicating a positive financial trend for the company.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an){return {layout:"default",data:[{noData:c,currentQuestion:e,textDescription:D,comeFrom:"AInvestShareLink",events:[],answerSource:k}],fetch:{},error:l,state:{sharePreviewModule:{loadJgySuccess:h,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:k,cache_builder:a,reply_action:"Answer",execute_mode:x,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did VXRT's revenue and expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did VXRT's revenue and expenses trend in Q4 2024?\",\"user_id\":\"dp53828499\",\"user_name\":\"\",\"trace_id\":\"76aa0907-9924-420b-8278-830bf6c2925d\",\"session_id\":\"76aa0907-9924-420b-8278-830bf6c2925d\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:E,title:F,summary:G,full_summary:"Vaxart Inc VXRT reported a quarterly adjusted loss of 5 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of three analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -11 cents to -8 cents per share. Revenue rose 368% to $15.19 million from a year ago; analysts expected $20.77 million. Vaxart Inc's reported EPS for the quarter was a loss of 5 cents. The company reported a quarterly loss of $11.99 million. Vaxart Inc shares had fallen by 11.8% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the biotechnology & medical research peer group is also \"strong buy\" Wall Street's median 12-month price target for Vaxart Inc is $4.00 This summary was machine generated from LSEG data March 20 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED  Dec. 31 2024 -0.10 -0.05 Beat  Sep. 30 2024 -0.10 -0.06 Beat  Jun. 30 2024 -0.03 -0.09 Missed  Mar. 31 2024 -0.14 -0.14 Met",url:H,image_url:a,video_url:a,publish_time:I,search_extra_info:{search_burial_info:{id:y,uid:J,ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]}}},simhash:"5bc9110fdb496e47",msg_id:y}}],answer_chain_name:N,agent_mode:O,native_answer:a,come_from:a,text_answer:D,trace_id:f,cost:20570,event_names:a,question:e,fallback_type:P,input_type:Q,fall_back_reason:{fall_back_type:P,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:f,first_return_cost:2917,cache_type:"no_cache",question_id:f,transfer_question:e,signal_type:"ON_COMPLETE",start_time:z,remote_svc:k,slots:[],answer_type:x,user_id:v,skill_name:A},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:f,session_id:f,user_id:v,question:e,source:k,raw_question:e,version:"3.4.1",action_name:A,nlu:{entity:[{type:R,value:"VXRT.O",market:S}]},output_time:z,deep_research:c,deep_thinking:c,agent_mode:O},extra:{}},{answer_path:m,section:{id:n,info_texts:["Thinking"],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:m,section:{id:n,info_texts:["Querying Stock: VXRT Revenue by Business, R&D Expenses, Sales Expenses in Fiscal 2024 Q4"],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b,status:T},logs:[],extra:{action:"Querying Stock",action_input:"VXRT Revenue by Business, R&D Expenses, Sales Expenses in Fiscal 2024 Q4",thought:"The user seeks to analyze VXRT's Q4 2024 revenue and expense trends. I should focus on its Q4 2024 revenue, R&D expenses, and sales expenses data. I will use FinQuery for the data mentioned above."}},{answer_path:d,section:{id:i,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:m,section:{id:n,info_texts:["Searching Web: Vaxart Q4 2024 revenue and expense analysis"],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b,status:T},logs:[],extra:{action:"Searching Web",action_input:"Vaxart Q4 2024 revenue and expense analysis",thought:"I am unable to obtain VXRT's Q4 2024 revenue and expense data using FinQuery, now I will try again using Search."}},{answer_path:d,section:{id:i,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:i,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:m,section:{id:n,info_texts:["Generating Answer"],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:q,voice_txt:"V",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:V,market_id:S,name:"Vaxart",domain:R},pos:h,section_id:p,txt:V,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:q,voice_txt:".",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:q,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:H,image_url:a,video_url:a,title:F,summary:G,index:E,publish_time:I,search_id:y,search_uid:J,search_ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:q,voice_txt:". This",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:i,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:i,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:i,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:q,voice_txt:"\n",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:m,section:{id:n,info_texts:["Completed"],show_type:o,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:r,query_text:r,trace_info:{item_id:"74072150d1e1e46145384e6b9018a6ff",item_type:j,item_name:r,rec_info:Z}},{display_text:s,query_text:s,trace_info:{item_id:"6d254e68b9c1f3d834a9bf4649ff2de7",item_type:j,item_name:s,rec_info:_}},{display_text:t,query_text:t,trace_info:{item_id:"13990930fe42ded98f964e88950a4e51",item_type:j,item_name:t,rec_info:$}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:h,type:"1",display2:c,url:a}},request_config:[{source_type:aa,related_name:ab}],puuid:B,tag:a,category:"custom",uuid:ac}],global:{urp_static_data:[{name:ab,value:{status_code:h,columns:[{type:u,index_name:ad,key:ad},{type:u,index_name:ae,key:ae},{type:u,index_name:af,key:af},{type:u,index_name:ag,key:ag},{type:u,index_name:ah,key:ah}],datas:[{send_text:r,item_type:j,rec_info:Z,display_text:r,rec_reason:a},{send_text:s,item_type:j,rec_info:_,display_text:s,rec_reason:a},{send_text:t,item_type:j,rec_info:$,display_text:t,rec_reason:a}],dataSize:aa,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ai,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:w,"min-height":"100%",position:aj,height:w},isMaterial:c,id:ai,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:h,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:C,componentUuid:ac,script:[{name:ak,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:C,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:C},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:w,position:aj,height:w},isMaterial:b,_id:19,id:ak,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:al,voice_txt:a,tracking_info:{},uuid:B},order:{is_auto:c,render_for:al,chart_type:"command",puuid:B}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:A,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:x,answer_chain_name:N},is_deep_research:c,deep_thinking:c,create_time:1746720749201},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:c,imageData:l,docsData:[],quoteData:l},tplType:"question"},events:am,agentId:a,param:{entity_info:{},add_info:{ori_question:e},event_list:am,client_ip:a,question:e,user_id:v,user_name:a,trace_id:f,session_id:f,source:k,input_type:Q}}],userId:v,userName:a,startTime:z,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:l,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:h,traceTableData:l,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-vxrts-revenue-and-expenses-trend-in-q4-2024-30d7b4\u002F",config:{_app:{basePath:an,assetsPath:an,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer","How did VXRT's revenue and expenses trend in Q4 2024?","76aa0907-9924-420b-8278-830bf6c2925d","signal",0,999,"llm_generated","ths_ainvest_lite_web",null,"progress\u002Fsearching_for",1000,"searching_for",2001,"rich_text","⚙️ What was VXRT's net income for Q4 2024?","🔎 What were VXRT's revenue figures for Q4 2024?","📊 How did VXRT's operating expenses change in Q4 2024 compared to previous quarters?","STR","dp53828499","auto","agent","c5a63c08b7b32d29_0",1746720728632,"review stocks","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","VXRT's revenue and expenses in Q4 2024 showed significant increases in revenue with a slight rise in expenses, compared to the same period in the previous year.\n\n1. **Revenue Trend**: VXRT's revenue for Q4 2024 was $15.19 million, a 368% increase from the $3.19 million reported in Q4 2023. This significant rise in revenue reflects the company's growth and the successful development of its vaccine candidates.\n2. **Expense Trend**: The company's R&D expenses and sales expenses for Q4 2024 are not available. However, the total expenses for the quarter were $11.99 million. Compared to Q4 2023, where the total expenses were not provided, it can be inferred that the expenses in Q4 2024 were higher due to the increased revenue.\n\n\n\nIn conclusion, VXRT experienced a substantial increase in revenue and an increase in expenses in Q4 2024, indicating a positive financial trend for the company.",2,"Vaxart Inc reports results for the quarter ended December 31 - Earnings Summary","Vaxart Inc VXRT reported a quarterly adjusted loss of 5 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -12 cents.The mean expectation of three analysts for the quarter was for a loss of 10 cents per share.Wall Street expect...","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Freuters.com,2025:newsml_L8N3Q32DS:0-vaxart-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary\u002F","2024-12-30","c5a63c08b7b32d29","oeqxkhszf","oeqxkhszf_layer","mix_en_config_hybrid_summary","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","thinking","VXRT's revenue and expenses in Q4 2024 showed significant increases in revenue with a slight rise in expenses, compared to the same period in the previous year.\n\n1","VXRT",". **Revenue Trend**: VXRT's revenue for Q4 2024 was $15.19 million, a 368% increase from the $3.19 million reported in Q4 2023[^2]",". This significant rise in revenue reflects the company's growth and the successful development of its vaccine candidates.\n2. **Expense Trend**: The company's R&D expenses and sales expenses for Q4 2024 are not available. However, the total expenses for the quarter were $11.99 million[^2]. Compared to Q4 2023, where the total expenses were not provided, it can be inferred that the expenses in Q4 2024 were higher due to the increased revenue.\n","\n``` visual\n{\"uuid\":\"83d80655-0f96-430a-8fbf-7cff59a2abce\"}\n```\n\nIn conclusion, VXRT experienced a substantial increase in revenue and an increase in expenses in Q4 2024, indicating a positive financial trend for the company.","2+679_496_21_554+0+0+76aa0907-9924-420b-8278-830bf6c2925d+74072150d1e1e46145384e6b9018a6ff+llm_generated+aimeTagAnalysis+0+0.02621188946068287+1","2+679_496_21_554+0+0+76aa0907-9924-420b-8278-830bf6c2925d+6d254e68b9c1f3d834a9bf4649ff2de7+llm_generated+aimeTagAnalysis+0+0.01928524672985077+2","2+679_496_21_554+0+0+76aa0907-9924-420b-8278-830bf6c2925d+13990930fe42ded98f964e88950a4e51+llm_generated+aimeTagAnalysis+0+0.011629123240709305+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>